ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 791,79
0,64%
Dow Jones
42 377,97
0,48%
DAX
19 473,63
1,32%
Brent Oil
71,655
0,99%
Bitcoin
65 864,40
1,05%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. NeuroSense Therapeutics Ltd (NRSN)

  7. NeuroSense Therapeutics Ltd (NRSN) Actualités

NRSN

NeuroSense Therapeutics (NRSN)

NeuroSense Therapeutics Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:NRSN
DateHeureSourceTitreSymboleSociété
24/09/202415h05PR Newswire (US)NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer'sNASDAQ:NRSNNeuroSense Therapeutics Ltd
24/09/202415h00PR Newswire (US)NeuroSense Regains Compliance with NASDAQ Minimum Bid Price RuleNASDAQ:NRSNNeuroSense Therapeutics Ltd
30/08/202423h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NRSNNeuroSense Therapeutics Ltd
30/08/202422h30PR Newswire (US)NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price NotificationNASDAQ:NRSNNeuroSense Therapeutics Ltd
16/08/202422h05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:NRSNNeuroSense Therapeutics Ltd
07/08/202420h00PR Newswire (US)NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market PriceNASDAQ:NRSNNeuroSense Therapeutics Ltd
01/08/202415h15PR Newswire (US)NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical TrialNASDAQ:NRSNNeuroSense Therapeutics Ltd
09/07/202415h27PR Newswire (US)NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease ProgressionNASDAQ:NRSNNeuroSense Therapeutics Ltd
01/07/202414h00PR Newswire (US)NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying DrugNASDAQ:NRSNNeuroSense Therapeutics Ltd
24/06/202415h00PR Newswire (US)NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial ResultsNASDAQ:NRSNNeuroSense Therapeutics Ltd
21/06/202422h30PR Newswire (US)NeuroSense Receives Delisting Notice from Nasdaq and Intends to AppealNASDAQ:NRSNNeuroSense Therapeutics Ltd
20/05/202415h00PR Newswire (US)NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development SummitNASDAQ:NRSNNeuroSense Therapeutics Ltd
14/05/202415h05PR Newswire (US)NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine LearningNASDAQ:NRSNNeuroSense Therapeutics Ltd
07/05/202414h45PR Newswire (US)NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS PatientsNASDAQ:NRSNNeuroSense Therapeutics Ltd
02/05/202415h19PR Newswire (US)NeuroSense Announces First Quarter 2024 Business UpdateNASDAQ:NRSNNeuroSense Therapeutics Ltd
22/04/202414h30PR Newswire (US)NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's DiseaseNASDAQ:NRSNNeuroSense Therapeutics Ltd
18/04/202414h30PR Newswire (US)NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual MeetingNASDAQ:NRSNNeuroSense Therapeutics Ltd
12/04/202414h30PR Newswire (US)NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024NASDAQ:NRSNNeuroSense Therapeutics Ltd
11/04/202401h16PR Newswire (US)NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private PlacementNASDAQ:NRSNNeuroSense Therapeutics Ltd
09/04/202414h30PR Newswire (US)NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and DiagnosticsNASDAQ:NRSNNeuroSense Therapeutics Ltd
05/04/202415h29PR Newswire (US)NeuroSense Announces Year End 2023 Financial Results and Provides Business UpdateNASDAQ:NRSNNeuroSense Therapeutics Ltd
21/02/202414h30PR Newswire (US)NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM TrialNASDAQ:NRSNNeuroSense Therapeutics Ltd
13/02/202419h20Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NRSNNeuroSense Therapeutics Ltd
09/01/202414h45PR Newswire (US)NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 CatalystsNASDAQ:NRSNNeuroSense Therapeutics Ltd
27/12/202323h03Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:NRSNNeuroSense Therapeutics Ltd
27/12/202323h00PR Newswire (US)NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity RequirementNASDAQ:NRSNNeuroSense Therapeutics Ltd
14/12/202315h24PR Newswire (US)NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS TrialNASDAQ:NRSNNeuroSense Therapeutics Ltd
05/12/202314h00PR Newswire (US)NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy EndpointsNASDAQ:NRSNNeuroSense Therapeutics Ltd
05/12/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:NRSNNeuroSense Therapeutics Ltd
04/12/202322h01PR Newswire (US)NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023NASDAQ:NRSNNeuroSense Therapeutics Ltd
 Showing the most relevant articles for your search:NASDAQ:NRSN

Dernières Valeurs Consultées

BOV
BEFV39R
BlackRock Institutional ...
LSE
AP24
Citi Fun 25
NASDAQ
ECDA
ECD Automotive Design
LSE
S7XP
Inv Estx Banks
LSE
1ANZ
Morti. Btl 52
LSE
NT49
Citi Fun 24
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés